aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2024. All rights reserved.
44 Tehama St, San Francisco, CA 94105
Privacy Policy
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
Cure: A telehealth platform connecting patients to healthcare services and 2500+ pharmacy products remotely.
Founded
2021
Cure is a telehealth platform founded in 2021 by Ali El-Ali and Manuel Aberle. It connects patients with local pharmacies offering over 2500 products through their app. The platform also provides access to healthcare professionals, including doctors and nurses, who offer remote medical care and advice.
Cure has made significant strides in enhancing accessibility to healthcare services, allowing patients to receive medical attention and pharmacy products from the comfort of their homes. This innovation has improved patient convenience and healthcare delivery efficiency.
Operating Status
Active
Main Product(s)
Telehealth, Pharmacy
Technology
Telemedicine
Model Types
SaaS, Platform
Revenue Type(s)
Recurring
Geographic Exposure
Global
When was Cure founded?
Cure was founded in 2021.
When was Cure’s last funding round?
Cure’s most recent funding round was for $15M (USD) in September 2022.
How many employees does Cure have?
Cure has 40 employees as of Mar 31, 2023.
How much has Cure raised to-date?
As of July 05, 2023, Cure has raised a total of $19.7M (USD) since Sep 15, 2022.
Add Comparison
Total Raised to Date
$19.7M
USD
Last Update Sep 15, 2022
Last Deal Details
$15M
USD
Sep 15, 2022
Series A
Total Employees Over Time
40
As of Mar 2023
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts